$4.52
-0.13(-2.80%)
Mkt Cap $3M
$3.09
$8.84
52-Week Range
At a Glance
AI-generatedENDRA Life Sciences Inc.
8-K
ENDRA Life Sciences reported a reduced net loss of $7.0 million for 2025, driven by lower operating expenses, and announced its Board has initiated a process to evaluate strategic alternatives to maximize shareholder value.$3M
Market Cap
—
Revenue
-$8M
Net Income
Employees21
Fundamentals
How The Business Makes Money
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Industry Medical - Diagnostics & Research
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001681682
ISINUS29273B5003
CUSIP29273B104
Phone734 335 0468
Address3600 Green Court, Ann Arbor, MI, 48105-1570, US
SEC EDGAR